AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
3.800
+0.050 (1.33%)
At close: Jul 3, 2025, 1:00 PM
3.830
+0.030 (0.79%)
After-hours: Jul 3, 2025, 4:57 PM EDT
AbCellera Biologics Revenue
AbCellera Biologics had revenue of $4.24M in the quarter ending March 31, 2025, a decrease of -57.45%. This brings the company's revenue in the last twelve months to $23.11M, down -35.41% year-over-year. In the year 2024, AbCellera Biologics had annual revenue of $28.83M, down -24.17%.
Revenue (ttm)
$23.11M
Revenue Growth
-35.41%
P/S Ratio
48.59
Revenue / Employee
$38,782
Employees
596
Market Cap
1.13B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ABCL News
- 4 weeks ago - AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 - Business Wire
- 7 weeks ago - AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause - Business Wire
- 7 weeks ago - AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit - Business Wire
- 7 weeks ago - AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting - Business Wire
- 2 months ago - AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - AbCellera Reports Q1 2025 Business Results - Business Wire
- 2 months ago - AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025 - Business Wire
- 3 months ago - AbCellera to Participate at Upcoming Investor Conferences in May and June - Business Wire